Background & Aims-It is a challenge to deliver nucleic acids to gastrointestinal (GI) tissues due to their size and need for intracellular delivery. They are also extremely susceptible to
INTRODUCTION
The gastrointestinal (GI) tract presents a striking opportunity for the delivery of therapeutics. It is characterized by a large surface area and is designed to absorb material 1 . These two features in particular make the GI tract a logical site for drug administration. However, the ability to absorb nutrients is facilitated by a harsh environment well suited to breaking down complex nutrients. Specifically, the low pH and wealth of proteases and nucleases makes the delivery of biologics via the GI tract extremely challenging 2 . This has largely limited GI luminal drug delivery to small molecules 3 . Indeed, the efficient delivery of biologics via the GI tract might present a paradigm shift in clinical and research settings, allowing for the local administration of highly effective biologics in the clinic to treat diseases like inflammatory bowel disease (IBD) 4, 5 .
More broadly, challenges in delivery have also hampered clinical development of new therapeutics for a host of diseases. The development of new therapeutics necessitates the targeting and validation of new therapeutic targets with an active molecule. However, drugging a target necessitates delivering the molecule to the biological target, the delivery of which, is non-trivial. In the case of IBD, for example, these challenges are highlighted by the development times of Alicaforsen and Mongersen, two new antisense therapies 6, 7 . The development times of these molecules, with Alicaforsen having been under development for Crohn's Disease as early as 1997 8 , underscores the difficulties in identifying, validating, and drugging new therapeutic targets. Beyond the targets of these two new drugs, mainly intercellular adhesion molecule-1 and SMAD7, respectively, lie a myriad of potential targets that might be effectively modulated to treat the underlying disease 9 . However, properly identifying a potential target and its function requires drugging it with an active biologic, the delivery of which, is challenging. This is particularly true in ulcerative colitis research, where the optimal therapeutic target has yet to be identified despite decades of intense research 10 .
These limitations highlight the glaring need for drug-independent methods of delivery. A platform that might enable the delivery of biologics and nucleic acids without the need for extensive formulation and nucleic acid modification could represent a paradigm shift in drug delivery science and have broad clinical impact. A physical enhancer, such as ultrasound, may enable formulation-independent delivery of biologics.
Ultrassound is a pressure wave with frequencies above 20 kHz. Clinically, ultrasound is widely used for imaging, lithotripsy and tumor ablation. Ultrasound has been shown to reversibly permeabilize tissue through a phenomenon known as transient cavitation 11 . This phenomenon has been investigated extensively for facilitating permeabilization of the skin in the context of transdermal drug delivery and received FDA-approval for the topical delivery of lidocaine 12 .
Aside from its use in clinical settings, ultrasound has also recently been noted to facilitate reversible permeabilization of cellular membranes allowing for intracellular delivery of fluorescent permeants 13 . This has been noted to result from cavitation events creating small defects in the cell membrane, allowing diffusion of species into the cell 13 . However, few studies exist on the use of ultrasound to facilitate intracellular delivery in vivo in complex biological settings, such as the GI tract.
Building on these two observations, we sought to investigate the use of ultrasound to facilitate permeabilization of the GI tract and simultaneously porate individual cells, enabling intracellular delivery. We chose the delivery of RNAs given the need for these therapeutics to be delivered into cells and because of the recognized difficulty in delivering this type of molecule currently 14 .
MATERIALS AND METHODS

Chemicals
Phosphate buffered saline (PBS), lysine-fixable 3 kDa dextran labeled with Texas Red, murine siRNA targeting Tnf mRNA (Stealth siRNA MSS211991), and DEPC-treated water were purchased from Invitrogen (Carlsbad, California). 14 C-labeled inulin was purchased from American Radiolabeled Chemicals (St. Louis, Missouri). Dextran sodium sulfate (DSS) was purchased from Affymetrix Inc. (Santa Clara, California). mRNA coding for firefly luciferase was purchased from TriLink Biotechnologies (San Diego, California). Dluciferin, Soluene-350, and Hionic-Fluor scintillation cocktail fluid were purchased from Perkin-Elmer (Waltham, Massachusetts).
Ex Vivo Experiments
Porcine Tissue Preparation-The MIT Committee on Animal Care approved all animal-related research aspects of this study. Colon tissue was procured from Yorkshire pigs within 20 minutes of the animal being euthanized and stored at 4°C. The tissue was used within 6 hours of procurement. Tissue was washed with PBS, sectioned into pieces approximately 2 cm by 2 cm in size, and mounted in 15 mm-diameter Franz diffusion cells (PermeGear, Hellertown, Pennsylvania) or 29 mm-diameter custom-made diffusion cells to accommodate different sized ultrasound horns. with the luminal side exposed to the donor chamber. After mounting all tissue, Franz cells were randomly assigned to either ultrasound or control experimental groups.
Ultrasound Administration-Immediately before administration, the donor chamber was filled with 1.5 mL of permeant solution. 14 C-labeled inulin was used as received at a concentration of 0.03 mg/mL and 3 kDa dextran tagged with Texas red at a concentration of 0.2 mg/mL in PBS. 20 kHz ultrasound was utilized to maximize transient cavitation events, which have previously been shown to be the primary mechanism of enhancement 15 . 20 kHz and 60 kHz ultrasound were generated with a 13 mm diameter VCX 500 and a 13 mm diameter custom-ordered probe, respectively (Sonics and Materials, Inc., Newtown, Connecticut). 1 MHz ultrasound was generated using a Dynatron D125 ultrasound probe (Dynatronics, Corporation, Salt Lake City, Utah). For all applications, the ultrasound probe tip was placed 3 mm away from the surface of the tissue. Ultrasound intensities were calibrated by calorimetry to 5 W/cm 2 , 9.6 W/cm 2 , and 1.5 W/cm 2 for 20 kHz, 60 kHz, and 1 MHz ultrasound, respectively. For frequency comparison studies, total applied ultrasound power and permeant contact time were kept constant across all three frequencies. For 3 kDa dextran, ultrasound was applied for 1 minute using a 50% duty cycle (5 s on, 5 s off).
After administration, the permeant was removed and the tissue thoroughly washed with PBS. Delivery into the tissue using 14 C-labeled inulin was quantified using a liquid scintillation counter (Perkin-Elmer, Waltham, Massachusetts) by solubilizing the tissue. Delivery of 3 kDa dextran was quantified by imaging the tissue with an IVIS fluorescence imager (Perkin-Elmer, Waltham, Massachusetts).
Multiphoton Microscopy-After delivery of 3 kDa dextran, tissue sections were fixed in 10% formalin overnight. They were then stained for 30 minutes with 4',6-diamidino-2phenylindole (DAPI) nuclear stain. After staining, the tissue was washed and imaged by the microscopy core facility in the Swanson Biotechnology Center (MIT). Specifically, an Olympus FV1000 Multiphoton Laser Scanning Microscope was used. Z-stack images were acquired with a step size of 5 µm to a total depth of 125 µm. The second harmonic (to show tissue architecture), DAPI, and dextran channels were acquired.
In Vivo Experiments
Animals-15-week old, female C57BL/6 mice were purchased from Charles River Laboratories (Wilmington, Massachusetts) for all studies. Each cage (group) of animals was used as received and assigned randomly to a particular experimental group by the researchers performing the work.
In Vivo Ultrasound Administration
For this study, a custom-designed 40 kHz ultrasound probe was manufactured to enable administration in the colon of mice (Sonics and Materials, Inc., Newtown, Connecticut). The shaft has a diameter of 2 mm and contains two, 3 mm diameter protrusions at halfwavelength intervals along the shaft to induce radial ultrasound activity. Ultrasound intensity was calibrated to 4.0 W by calorimetry. Ultrasound was administered by inserting the probe into the rectum and turning it on for 0.5 seconds.
kDa Dextran Delivery Study
In order to assess the potential for macromolecule delivery in mice in vivo, 3 kDa dextran tagged with Texas red was used as a model permeant. The dextran was diluted in PBS to a concentration of 0.33 mg/mL. Immediately before ultrasound administration, mice were sedated with isoflurane. 0.5 mL of the dextran solution was administered as an enema into the colon followed by ultrasound. The solution remained in the rectum for 2 minutes and then the colon was thoroughly lavaged with PBS and the animal returned to its cage. Immediately after, or two hours after ultrasound administration, animals were euthanized for the purpose of dextran quantification in the colon. Immediately after euthanization, the colon was carefully dissected out, placed on black backing, and imaged using an IVIS Fluorescent Imaging System (Perkin-Elmer, Waltham, Massachusetts). Settings utilized were an excitation of 570 nm, emission of 620 nm, binning value of 4, f-value of 2, and a field-ofview of 12.8. Exposure time was varied to ensure the total counts exceeded 6,000, according to the manufacturer's recommendations.
Colon samples were then fixed in 10% formalin and mounted in paraffin blocks for histological sectioning. Two, 8 µm-thick sections separated by a 200 µm step were used for subsequent imaging. These sections were imaged by the microscopy core facility in the Swanson Biotechnology Center (MIT). Samples were imaged using an Olympus FV-1000MP multiphoton microscope with a 25×, 1.05 N.A. objective. Excitation at 860 nm was achieved using a Ti-Sapphire pulsed laser (Spectra-Physics, Santa Clara, California). The resulting emission was collected with a 607/70 nm band-pass filter. Additionally, collagen was imaged using second harmonic generation at 430 nm. Discrete image channels were further processed using ImageJ (National Institutes of Health, Bethesda, Maryland).
Dextran Sodium Sulfate Colitis
Colitis induction and administration of ultrasound with or without siRNA targeting Tnf mRNA (Stealth siRNA MSS211991) was performed following previously published protocols with slight modifications 15, 16 . On day 1, mice were weighed and feces were collected. The animals' drinking water was then spiked with 3% w/v DSS (40-50 kDa). The water was given ad libitum and replaced with a fresh DSS solution on days 3 and 5. On day 7, the DSS water was removed and the animals given normal drinking water. All DSS used in the study was from the same manufacturer batch number to reduce variability.
Experimental therapies were administered starting on day 1. Each experimental group received either an enema containing siRNA targeting Tnf mRNA, siRNA targeting Tnf mRNA administered in combination with ultrasound, or siRNA targeting Tnf mRNA followed by insertion of the ultrasound probe without turning it on to control for any potential injury as a result of insertion. Specifically, 100 ng of siRNA in 200 µL DEPCtreated water was instilled in the rectum of mice sedated with isoflurane. Ultrasound was administered as described above followed immediately by a second dose of siRNA. Enemas were administered daily for six consecutive days.
Animal weight, fecal consistency, and the presence of fecal blood was monitored daily. Fecal consistency and bleeding were scored based on previously published protocols 15, 17 . Fecal consistency was scored as follows: (1) normal pellet, (2) stool easily crushed, (3) stool that is soft and watery with the presence of granules, or (4) diarrhea. Blood in the stool was confirmed by hemoccult testing. Negative hemoccult results were scored (1). Positive hemoccult results were further stratified: (2) feces with no visible blood at the time of collection, (3) feces with discrete blood speckles on the surface, or (4) feces covered with blood or observation of blood around the animal's anus. The total fecal score was determined by summing the consistency and fecal occult blood scores. Therefore, the total fecal score ranges from 2 (normal) to 8 (severe disease).
On day 8, weight and fecal score were determined and then the animals were sacrificed. The colon was dissected and a small portion frozen for quantification of TNF protein by ELISA. The remainder of the colon was fixed in 10% formalin. Fixed tissue was sectioned into 2-6 pieces and mounted in paraffin blocks. Two, 8 µm-thick sections from each block separated by a 200 µm step were stained with hematoxylin and eosin and mounted to slides.
Histological Scoring
Histology was scored in a blinded fashion by a clinical pathologist at Massachusetts General Hospital. Scoring was performed according to previously published protocols 15 : Specifically, normal colonic mucosa with the preservation of normal crypt architecture was assigned a score of 0. Tissue showing signs of inflammation was further stratified as follows: Tissue with shortened crypts with moderate inflammatory infiltrate above the muscularis mucosae (1), tissue with the base of the mucosa eliminated but demonstrating residual surface epithelium with the upper portion of the crypts preserved (2), tissue lacking any mucosa and demonstrating chronic inflammation of the lamina propria with residual surface epithelium present (3), and tissue showing complete effacement and erosion of the mucosa combined with fibrinopurulent debris. Each tissue cross-section was scored 0-4 weighted by a percentage involvement. The percent involvement-weighted score for each tissue section from all animals in a given experimental group were averaged to give the histology score for that experimental group.
TNF Protein Quantification
To determine colonic TNF protein levels, frozen colon tissue was homogenized in protease inhibitor solution in PBS using a bead-based homogenizer (Precellys 24, Bertin Technologies, France). Cell debris was pelleted by centrifugation for 10 minutes and the resulting supernatant collected. TNF protein levels were quantified using an ELISA kit following the manufacturer's protocol (ThermoFisher Scientific, Waltham, Massachusetts). TNF protein levels were normalized by total protein content, which was quantified using a BCA total protein assay kit following the manufacturer's protocol (ThermoFisher Scientific, Waltham, Massachusetts).
mRNA Synthesis, Delivery, and Quantification mRNA lipid nanoparticles (LNPs) were synthesized as previously described 18 . Briefly, the ethanol phase containing the lipids and the aqueous phase containing the mRNA were mixed in a microfluidic chip device. The aqueous phase contained 300 µg firefly luciferase mRNA (5-methylcytidine and pseudouridine substituted, 1mg/mL in 10mM TRIS-HCL), 150 µL of citrate (100 mM, pH 3), and 1050 µL of water. The ethanol phase contained the ionizable lipid ckk-E12 (3.0 mg, synthesized in our laboratory, as previously described 19 With the mice anesthetized, 300 µL of the LNP solution was administered in the colon and the ultrasound probe administered. Two, 0.5 second ultrasound exposures were administered over a 5-minute period. For control experiments, the probe was administered but not turned on. After administration the animals were returned to their cage. 24 hours post administration, mice were injected intraperitoneally with D-luciferin (0.2 mL; 10 mg/mL in PBS). 15 minutes after the injection, animals were euthanized and the colons dissected, opened, and bioluminescence measured using an IVIS fluorescence imager (Perkin-Elmer, Waltham, Massachusetts). The bioluminescence signal was quantified using Living Image software (Caliper Life Science, Hopkinton, Massachusetts).
Statistical Analysis
Statistical analysis of 3 kDa dextran delivery and mRNA delivery was performed using twotailed Student's t-tests to determine statistical significance. Statistical analysis for the in vivo mouse colitis work was performed using one-way analysis-of-variance (ANOVA) tests with multiple comparisons. Statistical significance was defined as P < 0.05. All calculations were performed in MatLab R2015b (MathWorks).
RESULTS
Ultrasound Enhances the Delivery of Macromolecules Ex Vivo
The delivery of macromolecules by ultrasound was investigated using fresh porcine tissue mounted in Franz diffusion cells ( Figure 1A ) using a range of ultrasound frequencies from 20 kHz to 1 MHz. Lower frequencies were hypothesized to result in greater enhancement because previous work has demonstrated transient cavitation, the predominant mechanism of enhancement, to inversely correlate with frequency 15, 20 . 14 C-labeled inulin (5 kDa) was used as a model permeant ( Figure 1B ). Additional ultrasound intensities were investigated to further characterize the impact on delivery. As expected, 20 kHz ultrasound provided the greatest level of enhancement over passive diffusion. 60 kHz ultrasound did enhance the delivery of inulin over passive diffusion but less so than that using 20 kHz ultrasound (P = . 003; Figure 1B ). 1 MHz ultrasound resulted in no enhancement in delivery over passive diffusion. As a result, further experiments focused on the use of frequencies < 60 kHz.
After determining an appropriate range of ultrasound frequencies, the distribution of permeant throughout tissue because of ultrasound-mediated delivery was determined. 3 kDa dextran tagged with Texas red was used as a model permeant to allow for visualization of the permeant after administration. Short, 1-minute 20 kHz ultrasound exposures were found to enhance the delivery of dextran almost 7-fold compared to passive diffusion in the same timeframe (P = .037; Figure 1C ). Confocal imaging demonstrated the dextran to be relatively homogenously dispersed throughout the tissue ( Figure 1D ). Conversely, negligible dextran signal was detectable in tissue not treated with ultrasound ( Figure 1E ). Higher magnification imaging showed colocalization of red 3 kDa dextran signal with blue signal from 4',6diamidino-2-phenylindole (DAPI) nuclear stain ( Figure 1D ). Additionally, the 3 kDa dextran signal at these sites appeared as punctated, discrete spots.
Colonic Macromolecule Delivery In Vivo mediated by Radial Ultrasound
To assess the potential for macromolecule delivery in vivo, a miniature probe-based macromolecule delivery protocol was developed. This enables radial emission of 40 kHz ultrasound locally in the colon so as to direct cavitation towards the mucosa, maximizing colonic mucosal macromolecule delivery (Figure 2A ). 3 kDa dextran was rectally administered into the colon followed by the placement of the ultrasound probe, as shown in Figure 2B . Short, ~0.5 second ultrasound exposures in vivo in mice were safe and well tolerated based on histological examination of colon tissue post administration (Figure 3 ). The use of ultrasound was found to enhance the delivery of 3 kDa dextran 3-fold compared to passive diffusion (P = .041; Figure 2C ). Further, the fluorescent signal from 3 kDa dextran was still significantly elevated in tissue samples two hours after administration using ultrasound (P = .031; Figure 2D ). Ultrasound was found to enable deeper penetration of the 3 kDa dextran immediately after administration ( Figure 2E ) compared to that achieved with passive diffusion ( Figure 2F ), resulting in greater fluorescent intensity two hours after administration.
Colonic Anti-Tnf mRNA Delivery by Radial Ultrasound in Mice
Having demonstrated the capacity for radial ultrasound to successfully deliver macromolecules in vivo in mice, the capacity to deliver unencapsulated antisense therapies was investigated. siRNA targeting Tnf mRNA (16.1 kDa) was chosen given the recognized enhancement in TNF protein levels in colonic tissue as a result of dextran sodium sulfate (DSS) administration 16, 21 . Disease induction followed previously published protocols ( Figure 3A) 16 . A 6-day administration regimen was chosen to allow for comparison to previously published work utilizing novel formulations of siRNA 16 . Experimental groups investigated included siRNA administered with simultaneous ultrasound, siRNA administered with simultaneous insertion of the ultrasound probe (Figure 2A ) without turning it on, siRNA alone, and ultrasound alone. Disease induction was confirmed through the use of an experimental group receiving no ultrasound or siRNA. The total fecal score (a combination of fecal consistency and occult bleeding) was quantified daily ( Figure 3B ). The total fecal score increased in all animals not receiving ultrasound, demonstrating disease induction and progression. In animals receiving siRNA in combination with ultrasound, however, the total fecal score never exceeded 4 ( Figure 3B ). By day 7 and beyond, animals receiving siRNA in combination with ultrasound had significantly better fecal scores than any other experimental group (P < .021). This also supports the safety and tolerability of ultrasound administration, underscored by those experimental groups receiving either ultrasound alone and those receiving insertion of the probe with siRNA having a total fecal score no more elevated than the disease only group.
After assessing the total fecal score on day 8, animals were sacrificed and the colon dissected to allow for histological evaluation and quantification of TNF protein by ELISA. Histology scores comprising the degree of inflammation and architectural distortion were determined in a blinded fashion ( Figure 3C ). Animals receiving siRNA in combination with ultrasound were found to have statistically lower histology scores than any other experimental group (P ≤ 4.1×10 −5 ), in agreement with the significantly better total fecal scores. Tissue from animals receiving siRNA with ultrasound showed minimal erosion of the epithelium and preservation of crypts. No evidence of macroscopic injury due to ultrasound administration was noted. The other experimental groups demonstrated greater erosion and significant shortening of the crypts. The improved total fecal score and histological score noting less inflammation were hypothesized to be a result of efficient suppression of TNF protein. Indeed, TNF protein levels normalized by total protein content of colon tissue samples were found to be 7 to 8-fold lower in animals receiving siRNA in combination with ultrasound than any other experimental group (Figure 3D , P ≤ .014). This knockdown was found to be a diffuse phenomenon, with statistically similar levels of TNF protein in tissue taken from proximal and distal locations (P = .9). This confirmed successful knockdown of Tnf mRNA.
Colonic mRNA Delivery in Mice using Radial Ultrasound
Having demonstrated the ability to deliver siRNA, we investigated the potential for localized delivery of mRNA directly to the colon. mRNA (~950 kDa) encoding the firefly luciferase was administered with ultrasound and found to be successfully translated locally in the colon, based on measured bioluminescent signal after administration of D-luciferin substrate (Figure 4 ). The measured bioluminescent signal from animals administered mRNA in combination with ultrasound was an order-of-magnitude higher than that from animals administered mRNA alone (P = .0025).
DISCUSSION
Here we present an investigation on the delivery of macromolecules locally in the GI tract using low-frequency ultrasound. Specifically we focused on the delivery of RNA, a molecule recognized for its significant susceptibility to rapid nuclease breakdown. The delivery of macromolecules through topical approaches in the GI tract in sufficient loads to exert a therapeutic effect presents a significant challenge given the barrier presented by GI tissue, limiting passive delivery of molecules greater than 500 Da 22 . Low frequency ultrasound (< 60 kHz) was found to enable significant enhancement in delivery of macromolecules. Highfrequency ultrasound (1 MHz) had no effect on delivery. Initial ex vivo evaluation of low frequency ultrasound-mediated delivery with a model macromolecule, Texas red-labeled 3 kDa dextran, was notable for evenly distributed signal throughout fresh porcine colonic tissue. Interestingly, areas in which the fluorescent 3 kDa dextran signal appeared to localize with the DAPI nuclear stain were observed ( Figure 1D ). This, in combination with the punctated appearance of the signal in certain regions, might suggest intracellular delivery of the 3 kDa dextran 23, 24 . This is thought to be a result of the transient cavitation events induced by the ultrasound impinging upon individual cells, creating pores in the cellular membrane through which dextran could diffuse. This has been observed in previous studies on ultrasound-mediated delivery to cell cultures, noting the capacity for ultrasound to facilitate cellular delivery 25 .
Given the apparent capacity to achieve intracellular delivery locally, we investigated the potential for delivering therapeutically-relevant molecules that require intracellular delivery. We chose siRNA targeting Tnf mRNA given the recent clinical developments in antisense therapies for IBD 6, 26 . Daily administration of ultrasound was found to be safe and well tolerated, even in the setting of a compromised mucosa due to colitis. Short, 0.5 second pulses of ultrasound were found to successfully enable the delivery of unencapsulated siRNA, suppressing Tnf mRNA and subsequent TNF protein production in a diffuse manner, resulting in improvements in the total fecal score and histological disease activity of colonic tissue in mice with DSS-induced colitis. Given the susceptibility of these molecules to degradation, it is surprising that such a robust response was achieved using naked siRNA and highlights the rapidity of ultrasound-mediated delivery. This represents, to the best of our knowledge, the first delivery of unencapsulated siRNA in vivo with therapeutic benefit. Even more surprising was the efficacy achieved considering the minimal dose administered. Indeed, the dose utilized was 30-fold lower than other published studies employing novel formulations encapsulating the siRNA administered via gavage and resulted in comparable efficacy 16 . The present dose was also lower than that utilized in other published studies evaluating intrarectal administration of formulated nanoparticles containing siRNA, and achieved superior suppression of TNF protein 27 . Considering the use of siRNA for gene silencing more broadly, even the best chemical formulations, gleaned from screens of thousands of compounds, in which the antisense molecule is encapsulated and protected, only show activity at doses almost 3× higher than that reported here 28 . These studies also administer the antisense through intravenous injection, avoiding the inhospitable environment of the GI tract. This significant dose-sparing is an especially important feature given that one of the significant hurdles to clinical adoption of antisense therapies, beyond the delivery of these species, is the cost of a potential dose, given their typically low bioavailability 29 .
In addition to clinical settings, the capacity to deliver naked, unformulated antisense molecules could present a major advance for drug target screening and validation. One particular challenge in the field of drug development is the ability to validate a molecule's target and action. This necessitates the successful formulation and delivery of a molecule to confirm its activity. However, formulation work required to enable the delivery of these complex molecules can significantly delay the development and validation of these drugs. The laborious nature of this work is underscored by the development time of Mongersen, for example, with the identification of SMAD7 occurring almost two decades ago 30 with subsequent elucidation of its relevance to chronic IBD 31, 32 . A technology that can enable the rapid delivery of new drug entities without the need for any formulation would present a major shift in drug discovery and development.
Finally, having demonstrated the capacity to deliver unformulated antisense therapies with significant therapeutic benefit, we investigated the potential for the delivery of mRNA locally to the colon. This would therefore demonstrate the capacity of ultrasound to enable both silencing of specific proteins, as well as the preferential production of other proteins. The latter capability could have benefits for the expression of complex epitopes locally to aid in the stimulation and modulation of immunologic responses for novel vaccines, for example 33 . mRNA encoding firefly luciferase was successfully delivered to the colon, resulting in significant production of the protein, assessed through bioluminescent measurement after administration of the substrate. To the best of our knowledge, there has been no report to date demonstrating the capacity to deliver mRNA locally in the colon. Indeed, this represents a major advance towards the eventual clinical use of mRNA 34 .
In conclusion, we demonstrated the capacity of ultrasound to mediate the efficient and rapid delivery of macromolecules ex vivo and in vivo with significant benefit. Naked siRNA targeting Tnf mRNA was successfully administered locally in the colon of mice with DSSinduced colitis, leading to a 7-fold reduction in TNF protein levels in colonic tissue compared to other experimental groups, resulting in superior control of colitis. Further, mRNA was successfully delivered locally in the colon, resulting in translation of firefly luciferase protein. Future studies will investigate the cell types taking up the oligos and whether certain populations can be targeted. This technology could prove invaluable in clinical settings for treating local GI-based diseases, as well as in research settings to expedite the identification, validation, and eventual translation of new therapeutics. 
